Chronic Heart Failure Market By Treatment Type (Pharmaceuticals, Medical Devices); By Drug Class (SGLT2 Inhibitors, ACE Inhibitors, ARBs, Beta-Blockers, Mineralocorticoid Receptor Antagonists, Ivabradine, Others); By Medical Device Type (Implantable Cardioverter Defibrillators, Cardiac Resynchronization Therapy Devices, Left Ventricular Assist Devices, Remote Monitoring Devices); By Disease Type (HFrEF, HFpEF); By End User (Hospitals, Specialty Cardiology Clinics, Ambulatory Surgical Centers, Homecare Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Chronic Heart Failure Market Size and How Is the Treatment Landscape Evolving? – (Updated On: 03-Sep-2026)

The Global Chronic Heart Failure Market was valued at USD 17.98 billion in 2025 and is projected to reach USD 28.74 billion by 2032, expanding at a CAGR of 6.93% during 2026–2032, according to Strategic Market Research.

 

The chronic heart failure treatment market is driven by a large and growing cardiovascular disease burden requiring long-term medication, hospitalization management, and advanced device-based interventions.  Approximately 64 million people worldwide live with heart failure, with global incidence estimated at 2.72 cases per 1,000 person-years. In the United States, about 6.7 million adults are affected, lifetime risk has reached approximately 24%, and heart failure accounted for 1.2 million primary hospitalizations among 

 

FDA-approved  SGLT2 inhibitors such as Farxiga (dapagliflozin) and Jardiance (empagliflozin), which provide cardiovascular protection; ARNIs such as Entresto (sacubitril/valsartan) that reduce cardiac workload; and MRAs including spironolactone and Kerendia (finerenone). Additional therapies include beta-blockers, ACE inhibitors, ARBs, sGC stimulators (Verquvo), and HCN channel blockers (Corlanor), creating a multi-class treatment landscape focused on improving heart function and reducing clinical events. 

 

In the United States, heart failure was mentioned on approximately 452,573 death certificates, representing 14.6% of all deaths, and contributes to a major cardiovascular mortality burden. Globally, cardiovascular diseases cause nearly 19.8 million deaths annually, reinforcing the need for innovative heart failure therapies.

 

Leading and Fastest-Growing Segments in the Chronic Heart Failure Market

Treatment Type:

• Leading Segment – Pharmaceuticals: Pharmaceuticals held 72.0% of the market, representing USD 12.946 billion in 2025, and are projected to grow at a CAGR of 7.25%. Their leadership reflects long-term multidrug therapy across chronic HFrEF and the expanding pharmacological treatment pathway for HFpEF. Pharmaceuticals are also the fastest-growing treatment-type segment.

 

Drug Class:

• Leading Segment – Others: The Others category accounted for 28.0% of pharmaceutical revenue, equivalent to USD 3.625 billion in 2025, with a CAGR of 6.9%. It includes widely used diuretics, vericiguat, and other adjunctive therapies addressing congestion and residual cardiovascular risk.

• Fastest-Growing Segment – SGLT2 Inhibitors: SGLT2 inhibitors held 24.0% of pharmaceutical revenue, or USD 3.107 billion in 2025, and are projected to grow at the fastest CAGR of 11.0%. Their expanding role across HFrEF and HFpEF is broadening the eligible treatment population.

 

Medical Device Type:

• Leading Segment – Implantable Cardioverter Defibrillators: ICDs accounted for 35.0% of the medical-device segment, representing USD 1.762 billion in 2025, with a CAGR of 4.4%. Their established role in preventing sudden cardiac death among eligible heart-failure patients supports their leading position.

• Fastest-Growing Segment – Remote Monitoring Devices: Remote monitoring devices represented 17.0%, or USD 0.856 billion in 2025, and are projected to grow at the fastest CAGR of 9.9%. Implantable pulmonary-pressure and multisensor technologies are enabling earlier identification of clinical deterioration outside hospitals.

 

Disease Type:

• Leading Segment – HFrEF: Heart failure with reduced ejection fraction accounted for 58.0% of the market, representing USD 10.428 billion in 2025, with a CAGR of 6.2%. Its leadership reflects established multidrug guideline-directed therapy and substantial utilization of ICD and CRT technologies.

• Fastest-Growing Segment – HFpEF: Heart failure with preserved ejection fraction represented 42.0%, or USD 7.552 billion in 2025, and is projected to grow at a CAGR of 7.89%. SGLT2 inhibitors, finerenone, cardiometabolic therapies, and emerging treatment approaches are expanding the historically limited therapeutic landscape.

 

End User:

• Leading Segment – Hospitals: Hospitals held 49.0% of the market, representing USD 8.810 billion in 2025, with a CAGR of 6.1%. Acute decompensation management, therapy initiation, cardiac imaging, and advanced device procedures keep hospitals at the center of heart-failure care.

• Fastest-Growing Segment – Homecare Settings: Homecare settings accounted for 14.0%, or USD 2.517 billion in 2025, and are projected to grow at the fastest CAGR of 9.5%. Remote physiological monitoring and structured post-discharge management are shifting more longitudinal care outside traditional clinical settings.

 

Geography:

• Leading Segment – North America: North America accounted for 42.0% of the global market, representing USD 7.552 billion in 2025, with a CAGR of 6.5%. Its leadership is supported by a large diagnosed population, strong cardiology infrastructure, access to newer therapies, and extensive use of advanced cardiac devices.

• Fastest-Growing Segment – Asia-Pacific: Asia-Pacific represented 21.0% of the market, or USD 3.776 billion in 2025, and is projected to grow at the fastest regional CAGR of 8.4%. Its large heart-failure population, improving specialist care, and widening access to modern pharmaceutical therapies create substantial room for market expansion.

 

Treatment and Drug Class Trends Transforming the Chronic Heart Failure Market

Pharmaceuticals accounted for 72.0% of the Chronic Heart Failure Market, representing USD 12.946 billion in 2025, and are projected to expand at a CAGR of 7.25% during 2026–2032. Their position reflects chronic multidrug treatment rather than dependence on a single medicine. HFSA reports that fewer than one in four eligible U.S. HFrEF patients receives complete quadruple guideline-directed medical therapy, indicating substantial room for greater utilization within the already diagnosed population.

Medical devices held the remaining 28.0%, or USD 5.034 billion in 2025, and are projected to grow at a CAGR of 6.08%. Device expenditure is concentrated among patients requiring defibrillation, ventricular resynchronization, hemodynamic monitoring, or mechanical circulatory support, producing considerably higher value per treated patient than routine generic pharmacotherapy.

SGLT2 inhibitors accounted for 24.0% of pharmaceutical revenue, generating USD 3.107 billion in 2025, and are expected to expand at an 11.0% CAGR. Their growth is driven by their established role as core, first-line therapies in chronic heart failure, where they significantly reduce hospitalizations and mortality outcomes.

ACE inhibitors held 10.0% of pharmaceutical revenue, or USD 1.295 billion in 2025, and are forecast to expand at a 4.0% CAGR. Their slower growth reflects a mature, highly genericized category, although their affordability and extensive clinical familiarity preserve treatment volume in cost-sensitive healthcare systems and in patients not receiving newer renin-angiotensin therapies.

ARBs represented 8.0%, or USD 1.036 billion, with a projected 4.6% CAGR. The category remains clinically relevant for patients unable to tolerate ACE inhibitors and also contributes to combination-based heart-failure treatment. Its mature pricing profile limits revenue expansion compared with SGLT2 inhibitors and newer MRAs.

Beta-blockers accounted for 13.0% of pharmaceutical revenue, representing USD 1.683 billion in 2025, and are projected to grow at 4.8%. They remain a foundational component of HFrEF therapy, particularly for reducing sympathetic cardiac stress and managing heart rate, but most established molecules are generic, making patient volume more important than premium pricing.

Mineralocorticoid receptor antagonists (MRAs) are essential guideline-recommended therapies in chronic heart failure management, as they help reduce hospitalizations and mortality by blocking the harmful effects of aldosterone on cardiac and renal function. In 2025, MRAs accounted for 12.0% of the pharmaceutical market, valued at approximately USD 1.553 billion. The segment is expected to expand steadily at a CAGR of 6.9%, driven by increasing heart failure prevalence, clinical adoption, and the growing demand for effective cardiovascular treatments.

Ivabradine accounted for 5.0% of pharmaceutical revenue, or USD 0.647 billion, and is projected to grow at a 5.9% CAGR. Its position remains narrower because treatment is limited to selected symptomatic HFrEF patients in sinus rhythm whose heart rate remains elevated despite other therapy.

Other pharmaceutical therapies accounted for 28.0%, equivalent to USD 3.625 billion in 2025, and are projected to expand at 6.9%. The category includes diuretics used extensively for congestion, soluble guanylate cyclase stimulation with vericiguat in selected worsening HFrEF patients, and other adjunctive treatments. Verquvo's FDA labeling focuses on symptomatic chronic heart failure with LVEF below 45% following a worsening event, giving it a more targeted commercial position than foundational therapies.

ARNI therapy is also commercially important but has not been assigned a separate quantitative share because the supplied drug-class segmentation already reconciles to 100%. Entresto combines sacubitril-mediated neprilysin inhibition with valsartan-mediated angiotensin-II receptor blockade and is FDA approved to reduce cardiovascular death and heart-failure hospitalization in adults with chronic heart failure, with benefits most clearly evident when LVEF is below normal.

 

Medical Devices Redefining Clinical Value in Chronic Heart Failure Care

Implantable cardioverter defibrillators accounted for 35.0% of the medical-device segment, representing USD 1.762 billion in 2025, and are forecast to expand at a CAGR of 4.4%. ICDs remain established for selected patients at significant risk of life-threatening ventricular arrhythmias. Medtronic's Cobalt and Cobalt XT platforms combine defibrillation with connected cardiac management, illustrating how established rhythm-management systems are being enhanced with monitoring and workflow capabilities.

Cardiac resynchronization therapy devices represented 25.0% of device revenue, or USD 1.259 billion, with a 5.2% CAGR. CRT remains concentrated in patients with ventricular dysfunction and electrical conduction abnormalities who remain symptomatic despite optimized medical therapy. Boston Scientific's RESONATE, MOMENTUM and VIGILANT CRT-D platforms integrate SmartCRT and HeartLogic features, combining therapeutic pacing with physiological monitoring rather than treating resynchronization as a standalone intervention.

Left ventricular assist devices accounted for 23.0%, or USD 1.158 billion in 2025, and are projected to expand at a 6.3% CAGR. Their unit volumes are lower than ICD or CRT procedures, but high per-patient treatment value supports a substantial revenue contribution. Abbott's HeartMate 3 provides short- and long-term mechanical circulatory support for advanced refractory left ventricular heart failure, including bridge-to-transplant, recovery, and destination-therapy pathways.

Remote monitoring devices accounted for 17.0% of the market, valued at USD 0.856 billion, and are expected to experience the fastest growth with a 9.9% CAGR. These devices enable continuous tracking of vital health indicators, such as heart rate, blood pressure, and weight, from patients’ homes. The collected data is securely transmitted to healthcare providers, allowing early detection of health changes, timely medical intervention, and effective management of heart failure to prevent disease progression and reduce hospitalizations.

 

Care Settings Reshaping the Chronic Heart Failure Market

Hospitals represented the largest segment of the Chronic Heart Failure (CHF) market, accounting for 49.0% of the market share, valued at USD 8.810 billion in 2025, and are expected to expand at a CAGR of 6.1% during the forecast period. This dominance is attributed to the critical role of hospitals in providing acute stabilization, advanced diagnostic procedures, specialized treatment, and multidisciplinary care management

Specialty cardiology clinics held 27.0%, or USD 4.855 billion, and are forecast to grow at 7.1%. Their role is becoming more valuable as treatment involves simultaneous management of several drug classes, monitoring of renal function and potassium, assessment of ejection fraction, and selection of patients for ICD, CRT, hemodynamic monitoring, or advanced-heart-failure programs.

Ambulatory surgical centers represented 10.0%, or USD 1.798 billion in 2025, and are expected to grow at a 6.6% CAGR. Their role remains selective, but outpatient cardiovascular procedures and implantable-monitoring workflows can migrate outside conventional inpatient care where patient risk, clinical infrastructure, reimbursement, and procedural requirements permit.

Homecare settings accounted for 14.0% of the market, valued at USD 2.517 billion, and are projected to experience the fastest end-user CAGR of 9.5%. This growth is driven by the increasing demand for personalized and continuous care solutions for chronic heart failure (CHF) management. Homecare services enable remote monitoring, timely interventions, and patient-centered support, helping reduce hospital readmission rates, enhance treatment adherence, and improve overall quality of life for CHF patients.

 

Regional Performance and Growth Outlook of the Chronic Heart Failure Market

North America held a dominant position in the Chronic Heart Failure Market, accounting for 42.0% of the global market share, valued at USD 7.552 billion in 2025, and is expected to grow at a CAGR of 6.5%. The region is experiencing a rising burden of chronic heart failure, driven by an aging population and evolving disease patterns. Although age-adjusted incidence rates show stabilization or a slight decline, the overall prevalence continues to increase significantly, creating sustained demand for advanced diagnostic and therapeutic solutions.

Europe represented 28.0%, or USD 5.034 billion in 2025, and is forecast to grow at 6.2%. European Society of Cardiology statistics indicate more than 9.4 million heart-failure cases across ESC member countries in 2023 and nearly 450,000 associated deaths in the latest available year. Strong specialist networks and rapid incorporation of SGLT2 inhibitors and newer HFpEF evidence support the market, while national reimbursement and health-technology assessment can produce uneven commercialization timelines between countries.

Asia-Pacific region contributed 21.0% of the global revenue, valued at USD 3.776 billion in 2025, and is expected to demonstrate the fastest regional growth with a CAGR of 8.4%. The region follows established clinical recommendations, including the APSC Consensus Statements on Chronic Heart Failure, to improve disease management and patient outcomes.

Latin America represents a significant public health opportunity, shaped by evolving healthcare systems and increasing disease burden. In 2025, the region accounted for 5.0% of the global market, valued at USD 0.899 billion, and is expected to expand at a CAGR of 7.4%. This growth reflects rising awareness, improved access to advanced therapies, and ongoing efforts to enhance CHF care outcomes across Latin American countries.

Middle East & Africa accounted for 4.0%, or USD 0.719 billion, and are forecast to grow at 7.8%. Africa alone was estimated to have approximately 7.8 million left-heart-failure cases in the GBD-based regional analysis, but treatment intensity varies substantially. Gulf markets offer stronger access to advanced medicines and cardiovascular devices, while many African healthcare systems remain more dependent on essential generic pharmacotherapy, hospital-based management, and improving diagnostic and specialist capacity.

 

Competitive Forces Driving Innovation in the Chronic Heart Failure Market

Competition in the Chronic Heart Failure Market increasingly spans more than individual drug classes. Pharmaceutical companies compete through broader ejection-fraction indications, cardiorenal positioning, hospitalization reduction, treatment convenience, and evidence in high-risk patient groups, while device companies compete through implant longevity, remote physiological monitoring, advanced-heart-failure support, and integration with clinical workflows. Pipeline competition is particularly active in HFpEF, inflammation-targeted therapy, and implantable or interatrial pressure-management technologies.

Novartis

Novartis' principal chronic-heart-failure product is Entresto, containing sacubitril and valsartan. The ARNI is FDA approved to reduce cardiovascular death and heart-failure hospitalization in adults with chronic heart failure, with benefits most clearly demonstrated in patients whose LVEF is below normal. Its established role gives Novartis strong exposure to HFrEF, although mature-product pricing and expanding therapeutic alternatives are changing competitive economics.

AstraZeneca

AstraZeneca competes through Farxiga, or dapagliflozin. The FDA-approved SGLT2 inhibitor is indicated to reduce cardiovascular death, heart-failure hospitalization, and urgent HF visits in adults with heart failure. Its additional chronic-kidney-disease and diabetes indications allow AstraZeneca to address the overlapping cardiovascular-kidney-metabolic profile common among chronic-HF patients.

Boehringer Ingelheim and Eli Lilly

The alliance competes through Jardiance, or empagliflozin, an FDA-approved SGLT2 inhibitor indicated to reduce cardiovascular death and heart-failure hospitalization in adults with heart failure. Its positioning across HF, chronic kidney disease, and type 2 diabetes places the product directly against dapagliflozin in a broad cardiorenal population rather than within a narrowly defined HFrEF niche.

Bayer

Bayer's portfolio includes Kerendia and a role in the development of Verquvo. Kerendia's July 2025 U.S. heart-failure indication is strategically important because finerenone is now approved for adults with HF and LVEF ≥40%, covering a major HFmrEF/HFpEF population. Finerenone selectively blocks the mineralocorticoid receptor and provides a differentiated branded alternative to older steroidal MRAs.

Merck & Co.

Merck participates through Verquvo, or vericiguat, developed with Bayer. Vericiguat stimulates soluble guanylate cyclase and is positioned for adults with symptomatic chronic heart failure and LVEF below 45% following a recent worsening-HF event. Its commercial niche is therefore concentrated in patients with substantial residual risk after hospitalization or outpatient intravenous diuretic treatment.

Lexicon Pharmaceuticals

Lexicon markets Inpefa, or sotagliflozin, in the United States. The dual SGLT1/SGLT2 inhibitor is FDA approved to reduce cardiovascular death, HF hospitalization, and urgent HF visits in adults with heart failure or adults with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk. Lexicon reported in August 2026 that Inpefa remains commercially available for U.S. heart failure, while partner Viatris is pursuing additional ex-U.S. commercialization.

Abbott

Abbott has a differentiated device portfolio spanning both chronic monitoring and advanced mechanical support. CardioMEMS wirelessly measures pulmonary-artery pressure to guide treatment before overt decompensation, while HeartMate 3 provides mechanical circulatory support in advanced refractory left ventricular failure. This gives Abbott exposure to both hospitalization-prevention strategies and high-value Stage D heart-failure treatment.

Edwards Lifesciences

Edwards entered implantable heart-failure monitoring through its acquisition of Endotronix. The Cordella Pulmonary Artery Sensor System received FDA premarket approval in June 2024 for eligible NYHA Class III patients and transmits pulmonary-artery-pressure data from the home to assist clinical management. Cordella adds another major commercial platform to the remote-monitoring segment alongside CardioMEMS.

Medtronic

Medtronic's chronic-HF portfolio includes Cobalt XT, Cobalt and Crome CRT-D systems, with indications covering selected heart-failure populations requiring resynchronization and protection from ventricular arrhythmias. The company's completed ALLEVIATE-HF study also evaluated a management pathway combining an insertable cardiac monitor with a device-based risk algorithm, reflecting its broader focus on predictive monitoring alongside implanted rhythm therapy.

Boston Scientific

Boston Scientific combines CRT-D and ICD platforms with HeartLogic, an FDA-approved multisensor heart-failure diagnostic. HeartLogic aggregates physiological trends into a composite index and provides alerts of potential worsening HF. Products such as RESONATE, MOMENTUM and VIGILANT therefore compete on both therapeutic rhythm management and longitudinal remote assessment.

Novo Nordisk

Novo Nordisk is an important emerging pipeline competitor rather than an established chronic-HF drug supplier. Ziltivekimab is an investigational, fully human monoclonal antibody targeting the IL-6 ligand to reduce cardiovascular inflammation. Its Phase III HERMES study is evaluating cardiovascular death, HF hospitalization, and urgent HF visits in patients with HFmrEF or HFpEF and systemic inflammation, creating a potential new biological treatment approach if outcome data are positive.

 

Analyst Commentary:The Next Breakthrough Wave in Chronic Heart Failure

The most important therapeutic breakthrough through 2032 is likely to emerge in HFpEF, where treatment options have historically been limited. Finerenone has strong near-term potential because its approval in patients with LVEF of at least 40% expands the role of nonsteroidal MRAs across HFmrEF and HFpEF. At the same time, tirzepatide and other incretin-based therapies could reshape obesity-related HFpEF by addressing an underlying metabolic driver rather than treating cardiac dysfunction alone. This may create a new cardiometabolic treatment pathway alongside SGLT2 inhibitors.

Among pipeline medicines, ziltivekimab represents one of the highest-impact opportunities. Its Phase III HERMES program is evaluating IL-6 inhibition in patients with HFmrEF or HFpEF and systemic inflammation. Positive outcomes could establish inflammation as a new therapeutic target and potentially create an entirely new biologic drug class in heart failure. However, its commercial potential remains dependent on successful cardiovascular outcome data.

In devices, implantable pulmonary-artery-pressure monitoring is positioned for the strongest near-term adoption. Platforms such as CardioMEMS and Cordella can identify worsening hemodynamics before overt symptoms develop, supporting earlier intervention and potentially reducing hospital admissions. Their future value could increase further as sensor data are integrated with predictive algorithms and remote-care platforms.

A more disruptive but higher-risk opportunity is interatrial shunting. Technologies being developed by Alleviant Medical and Corvia Medical aim to directly reduce elevated cardiac filling pressures, particularly in HFpEF. If pivotal trials demonstrate clear reductions in heart-failure events, interatrial shunting could create a new interventional treatment category. Overall, HFpEF therapies, cardiometabolic drugs, inflammation-targeted biologics, and predictive hemodynamic monitoring are the areas most likely to redefine chronic heart failure treatment through 2032.

 

Chronic Heart Failure Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 17.98 Billion
Revenue Forecast in 2032	USD 28.74 Billion
Overall Growth Rate	CAGR of 6.93% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Drug Class, By Medical Device Type, By Disease Type, By End User, By Geography
By Treatment Type	Pharmaceuticals, Medical Devices
By Drug Class	SGLT2 Inhibitors, ACE Inhibitors, ARBs, Beta-Blockers, Mineralocorticoid Receptor Antagonists, Ivabradine, Others
By Medical Device Type	Implantable Cardioverter Defibrillators, Cardiac Resynchronization Therapy Devices, Left Ventricular Assist Devices, Remote Monitoring Devices
By Disease Type	HFrEF, HFpEF
By End User	Hospitals, Specialty Cardiology Clinics, Ambulatory Surgical Centers, Homecare Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing cardiovascular disease burden, long-term multidrug treatment, expanding HFpEF therapies, rising use of advanced cardiac devices, implantable pulmonary-artery-pressure monitoring, connected homecare, and predictive hemodynamic monitoring
Customization Option	Available upon request